Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

T-Cell Reconstitution after Unrelated Donor HSCT Using Immunotherapy with CD25/71 Allodepleted Donor T Cells: Results of the Randomised Icat Study

Blood (2019) 134 (Supplement_1): 1995.

https://doi.org/10.1182/blood-2019-124404

Published: 2019

Journal Articles

Absence of Damaging Effects of Stem Cell Donation in Unrelated Donors Assessed By FISH and Gene Variance Screening

Elisabeth P. Nacheva, MD PhD, Trudy Ahyee, C Navarette, Juanah Addada, MDPhDFRCP, Rachel Pawson, Richard Syzdlo, PhD, Stephen Mackinnon, MD, Bronwen E. Shaw, MD PhD, J. Alejandro Madrigal, MDPhDDSc,FRCP,FRCPath

Blood (2019) 134 (Supplement_1): 4474.

https://doi.org/10.1182/blood-2019-131931

Published: 2019

Journal Articles

Successful Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation in Adults with Inherited Primary Immunodeficiency (PID)

Emma C Morris, MD PhD, Thomas Andrew Fox, MRCP, Siobhan Burns, MD PhD, Ben Carpenter, MD, Kirsty J Thomson, MD, David Lowe, MD PhD, Adele K. Fielding, MB BS, PhD FRCP, FRCPath, Karl S Peggs, MD, Panagiotis Kottaridis, FRCPath, PhD MSc, Victoria Grandage, FRCPath, MRCP, PhD, Shari Denovan, RN, Sarah Grace, RN, Julia Dahlstrom, RN, Sarita Workman, RN, Andrew Symes, RN, Stephen Mackinnon, MD, Ronjon Chakraverty, BMBS, PhD, Rachael Hough, MD BMBS, FRCP, FRCPath

Blood (2016) 128 (22): 4681.

https://doi.org/10.1182/blood.V128.22.4681.4681

Published: 2016

Journal Articles

Long-Term Outcome of Allogeneic Stem Cell Transplantation (allo-SCT) in Patients with Waldenstrom Macroglobulinemia (WM)-a Retrospective Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Charalampia Kyriakou, Ariane Boumendil, PhD, Herve Finel, Norbert Schmitz, MD, PhD, Henrik Sengeloev, MD, Stephen Mackinnon, MD, Didier Blaise, MD PhD, Patrice Chevallier, MD PhD, Paul Browne, MD, Charles Craddock, MD PhD, Dietger W. Niederwieser, MD, Johannes Schetelig, MD PhD, Stig Lenhoff, Nathalie Fegueux, MD, Silvia Montoto, MD, Peter Dreger, MD PhD

Blood (2016) 128 (22): 4661.

https://doi.org/10.1182/blood.V128.22.4661.4661

Published: 2016

Journal Articles

Alternative Donors (Umbilical Cord Blood and Haploidentical Donors) for Allogeneic Stem Cell Transplantation in Relapsed / Refractory Hodgkin Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party and the Spanish Group of Stem Cell Transplantation (GETH)

Blood (2015) 126 (23): 4399.

https://doi.org/10.1182/blood.V126.23.4399.4399

Published: 2015

Journal Articles

Equality Of Access To Transplant For Ethnic Minority Patients Through Use Of Cord Blood and Haploidentical Transplants

Robert N Lown, MD, Steven GE Marsh, PhD, Helen Blake, BSc, Sergio Querol, MD, PhD, Irina Evseeva, PhD, Stephen Mackinnon, MD, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Michael Potter, MD PhD, Nigel Russell, MD, Charles Craddock, MD DPhil, J. Alejandro Madrigal, MD, PhD, Bronwen E. Shaw, MBChB, MRCP, PhD, FRCPath

Blood (2013) 122 (21): 2138.

https://doi.org/10.1182/blood.V122.21.2138.2138

Published: 2013

Journal Articles

Cytomegalovirus Drives Mixed Chimerism Following T-Cell Depleted Allogeneic HSCT, Providing Protective Immunity In The Absence Of GvHD

Rob S Sellar, MBBS, Frederick Arce Vargas, PhD, Jake Henry, Simon Thomas, PhD, Alka Stansfield, Stephanie Verfuerth, PhD, Sarah C Charrot, MBBS, Rachael E Hough, MD, Sergio A Quezada, PhD, Kirsty J Thomson, MD, Stephen Mackinnon, MD, Karl S Peggs, MD

Blood (2013) 122 (21): 4524.

https://doi.org/10.1182/blood.V122.21.4524.4524

Published: 2013

Journal Articles

Defining The Optimal Dose Of Alemtuzumab In Unrelated Donor Reduced Intensity Allografts: A UK Retrospective Study

Kile Green, BSc(Hons), Rob Sellar, MD, Laura Jardine, MD, Janice Ward, Paul Ferguson, MD, Pip Nicolson, MD, Kim Pearce, PhD, Venetia Bigley, MD, PhD, Graham Jackson, MD, Sandeep Nagra, MD, Anne M Dickinson, PhD, Kirsty Thomson, MD, Stephen Mackinnon, MD, Charles Craddock, MD, Matthew P. Collin, MD, PhD, Karl S Peggs, MD

Blood (2013) 122 (21): 4540.

https://doi.org/10.1182/blood.V122.21.4540.4540

Published: 2013

Journal Articles

Donor Attrition At The Confirmatory Typing Stage Results In Poorer Transplant Options For Patients Of All Ethnicities

Robert N Lown, MD, Steven GE Marsh, PhD, Helen Blake, BSc, Irina Evseeva, PhD, Stephen Mackinnon, MD, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Michael N Potter, MBBS, PhD, Nigel H. Russell, MD, Charles Craddock, MD DPhil, J. Alejandro Madrigal, MD, PhD, Bronwen E. Shaw, MBChB, MRCP, PhD, FRCPath

Blood (2013) 122 (21): 3377.

https://doi.org/10.1182/blood.V122.21.3377.3377

Published: 2013

Journal Articles

Results of a Phase 1 Clinical Trial of Allogeneic Tumor-Primed Natural Killer Cells in AML

Panagiotis Kottaridis, MD, PhD, Maria Tsirogianni, MD, Janet North, BSc, MSc, Chloe Marden, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath

Blood (2011) 118 (21): 946.

https://doi.org/10.1182/blood.V118.21.946.946

Published: 2011

Journal Articles

Allogeneic Stem Cell Transplantation Induces Long Term Survival in Pateitns with Advanced Chronic Myeloid Leukaemia:A Study of the British Society for Blood and Marrow Transplantation,

Gordon Cook, Keiren Kirkland, Julia Lee, Rachel M Pearce, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Richard E. Clark, MD, Stephen Mackinnon, MD, David I. Marks, MBBS, PHD

Blood (2011) 118 (21): 4125.

https://doi.org/10.1182/blood.V118.21.4125.4125

Published: 2011

Journal Articles

A Simple Prognostic Score to Predict Short and Long-Term Survival Following ICU Admission in Critically Ill Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients: Improved Survival Following Reduced Intensity Conditioning

William Townsend, Ailsa Holroyd, Rachel M Pearce, Stephen Mackinnon, MD, Anthony H. Goldstone, FRCP, FRCPath, David C Linch, MD FMedSci, Karl S Peggs, MD, Kirsty Thomson, MD, Mervyn Singer, Prakesh Naik, David Howell, Emma Morris, MD

Blood (2011) 118 (21): 146.

https://doi.org/10.1182/blood.V118.21.146.146

Published: 2011

Journal Articles

CMV-Reactive T Cells Can Be Isolated From G-CSF Mobilised Peripheral Blood Apheresates.

Edward R Samuel, MSc, Katy Newton, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath

Blood (2010) 116 (21): 1276.

https://doi.org/10.1182/blood.V116.21.1276.1276

Published: 2010

Journal Articles

CMV-Reactive γ/δ T Cells Are Equivalent to Their α/β Counterparts In the Lysis of CMV-Infected Targets – Potential for Post Transplant Adoptive Immunotherapy.

Andrea Knight, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath

Blood (2010) 116 (21): 1277.

https://doi.org/10.1182/blood.V116.21.1277.1277

Published: 2010

Journal Articles

Adoptive Transfer of CMV-Specific Donor T Cells Following Allogeneic Transplantation Leads to Rapid and Safe Systemic Reconstitution.

Karl S Peggs, MD, Kirsty Thomson, MD, Edward Samuel, BSc, MSc, Gemma Dyer, Julie Armoogum, Kwok Pang, BSc, MSc, Ronjon Chakraverty, MD, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath

Blood (2009) 114 (22): 44.

https://doi.org/10.1182/blood.V114.22.44.44

Published: 2009

Journal Articles

Donor Lymphocyte Infusions Induce High Response Rates and Durable Salvage in Relapsed Hodgkin Lymphoma Post T Cell Depleted Allogeneic Transplantation.

Karl S Peggs, MD, Kirsty Thomson, MD, Emma Morris, MD, Noha Chowdhry, Stephanie Verfuerth, PhD, Panos Kottaridis, Anthony H. Goldstone, FRCP, FRCPath, Kirit Ardeshna, MD, David Linch, Ronjon Chakraverty, MD, PhD, Stephen Mackinnon, MD

Blood (2009) 114 (22): 200.

https://doi.org/10.1182/blood.V114.22.200.200

Published: 2009

Journal Articles

CMV-Reactive Gamma/Delta T Cells Expanded From CMV Seronegative Normal Healthy Individuals Lyse CMV-Infected Targets – Potential Adoptive Immunotherapy for Recipients of Stem Cell Transplants From CMV Seronegative Donors.

Andrea Knight, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath

Blood (2009) 114 (22): 2233.

https://doi.org/10.1182/blood.V114.22.2233.2233

Published: 2009

Journal Articles

T Cell Depletion with Alemtuzumab Is Associated with a High Incidence of EBV Viraemia but Low Risk of PTLD Following Allogeneic Stem Cell Transplantation

Ben Carpenter, MD, Maria Dimopoulou, MD, Nilusha Manji, Tanzina Haque, MD, Claire Atkinson, MD, Sarah Grace, Stephen Mackinnon, MD, Ronjon Chakraverty, MD

Blood (2008) 112 (11): 1177.

https://doi.org/10.1182/blood.V112.11.1177.1177

Published: 2008

Journal Articles

Mismatch at 1-2 HLA Loci Does Not Reduce Survival Following Alemtuzumab-Based Reduced Intensity Unrelated Donor Allogeneic Transplantation

Adam J Mead, Kirsty J Thomson, Emma C Morris, Ronjon Chakraverty, David C. Linch, FRCP, Stephen Mackinnon, MD, Karl S Peggs

Blood (2008) 112 (11): 3008.

https://doi.org/10.1182/blood.V112.11.3008.3008

Published: 2008

Journal Articles

Pre-Transplant PET Status May Not Impact on Survival Following Reduced-Intensity Allogeneic Stem-Cell Transplant for Lymphoma. However, Post-Transplant Surveillance with PET May Be Important for Directing Immunotherapy.

Jonathan R Lambert, MRCP, Jamshed B Bomanji, PhD, Nichola Cooper, MRCP, MRCPath, MD, Daniel P Hart, MRCP, Karl Peggs, Kirsty Thomson, Peter J Ell, FMedSci, Stephen Mackinnon, MD

Blood (2008) 112 (11): 3256.

https://doi.org/10.1182/blood.V112.11.3256.3256

Published: 2008

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

T-Cell Reconstitution after Unrelated Donor HSCT Using Immunotherapy with CD25/71 Allodepleted Donor T Cells: Results of the Randomised Icat Study

Absence of Damaging Effects of Stem Cell Donation in Unrelated Donors Assessed By FISH and Gene Variance Screening

Successful Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation in Adults with Inherited Primary Immunodeficiency (PID)

Long-Term Outcome of Allogeneic Stem Cell Transplantation (allo-SCT) in Patients with Waldenstrom Macroglobulinemia (WM)-a Retrospective Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Alternative Donors (Umbilical Cord Blood and Haploidentical Donors) for Allogeneic Stem Cell Transplantation in Relapsed / Refractory Hodgkin Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party and the Spanish Group of Stem Cell Transplantation (GETH)

Equality Of Access To Transplant For Ethnic Minority Patients Through Use Of Cord Blood and Haploidentical Transplants

Cytomegalovirus Drives Mixed Chimerism Following T-Cell Depleted Allogeneic HSCT, Providing Protective Immunity In The Absence Of GvHD

Defining The Optimal Dose Of Alemtuzumab In Unrelated Donor Reduced Intensity Allografts: A UK Retrospective Study

Donor Attrition At The Confirmatory Typing Stage Results In Poorer Transplant Options For Patients Of All Ethnicities

Results of a Phase 1 Clinical Trial of Allogeneic Tumor-Primed Natural Killer Cells in AML

Allogeneic Stem Cell Transplantation Induces Long Term Survival in Pateitns with Advanced Chronic Myeloid Leukaemia:A Study of the British Society for Blood and Marrow Transplantation,

A Simple Prognostic Score to Predict Short and Long-Term Survival Following ICU Admission in Critically Ill Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients: Improved Survival Following Reduced Intensity Conditioning

CMV-Reactive T Cells Can Be Isolated From G-CSF Mobilised Peripheral Blood Apheresates.

CMV-Reactive γ/δ T Cells Are Equivalent to Their α/β Counterparts In the Lysis of CMV-Infected Targets – Potential for Post Transplant Adoptive Immunotherapy.

Adoptive Transfer of CMV-Specific Donor T Cells Following Allogeneic Transplantation Leads to Rapid and Safe Systemic Reconstitution.

Donor Lymphocyte Infusions Induce High Response Rates and Durable Salvage in Relapsed Hodgkin Lymphoma Post T Cell Depleted Allogeneic Transplantation.

CMV-Reactive Gamma/Delta T Cells Expanded From CMV Seronegative Normal Healthy Individuals Lyse CMV-Infected Targets – Potential Adoptive Immunotherapy for Recipients of Stem Cell Transplants From CMV Seronegative Donors.

T Cell Depletion with Alemtuzumab Is Associated with a High Incidence of EBV Viraemia but Low Risk of PTLD Following Allogeneic Stem Cell Transplantation

Mismatch at 1-2 HLA Loci Does Not Reduce Survival Following Alemtuzumab-Based Reduced Intensity Unrelated Donor Allogeneic Transplantation

Pre-Transplant PET Status May Not Impact on Survival Following Reduced-Intensity Allogeneic Stem-Cell Transplant for Lymphoma. However, Post-Transplant Surveillance with PET May Be Important for Directing Immunotherapy.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only